Cargando…

Systematic review of the evidence relating FEV(1 )decline to giving up smoking

BACKGROUND: The rate of forced expiratory volume in 1 second (FEV(1)) decline ("beta") is a marker of chronic obstructive pulmonary disease risk. The reduction in beta after quitting smoking is an upper limit for the reduction achievable from switching to novel nicotine delivery products....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Peter N, Fry, John S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017006/ https://www.ncbi.nlm.nih.gov/pubmed/21156048 http://dx.doi.org/10.1186/1741-7015-8-84

Ejemplares similares

Systematic review with meta-analysis of the epidemiological evidence relating FEV(1) decline to lung cancer risk
por: Fry, John S, et al.
Publicado: (2012)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

A blood and bronchoalveolar lavage protein signature of rapid FEV(1) decline in smoking-associated COPD
por: DiLillo, Katarina M., et al.
Publicado: (2023)

Inhaled corticosteroids and FEV(1) decline in chronic obstructive pulmonary disease: a systematic review
por: Whittaker, Hannah R., et al.
Publicado: (2019)

Rapid FEV(1)/FVC Decline Is Related With Incidence of Obstructive Lung Disease and Mortality in General Population
por: Choi, Kwang Yong, et al.
Publicado: (2022)

Obstructive sleep apnoea accelerates FEV(1) decline in asthmatic patients
por: Wang, Tsai-Yu, et al.
Publicado: (2017)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

FEV(1) decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort
por: Backman, Helena, et al.
Publicado: (2020)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV(1): a longitudinal retrospective cohort study
por: Masuko, Hironori, et al.
Publicado: (2011)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Understanding the natural progression in %FEV(1) decline in patients with cystic fibrosis: a longitudinal study
por: Taylor-Robinson, David, et al.
Publicado: (2012)

Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART
por: Samperiz, Gloria, et al.
Publicado: (2019)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
por: Dhaygude, Kishor, et al.
Publicado: (2019)

Polymorphisms of ATF6B Are Potentially Associated With FEV1 Decline by Aspirin Provocation in Asthmatics
por: Park, Tae-Joon, et al.
Publicado: (2014)

Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study
por: Talini, Donatella, et al.
Publicado: (2015)

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Cut-off value of FEV(1)/FEV(6) as a surrogate for FEV(1)/FVC for detecting airway obstruction in a Korean population
por: Chung, Kyung Soo, et al.
Publicado: (2016)

Factors Associated with the Expression of ACE2 in Human Lung Tissue: Pathological Evidence from Patients with Normal FEV(1) and FEV(1)/FVC
por: Bao, Wuping, et al.
Publicado: (2021)

Association between 25-hydroxy vitamin D and lung function (FEV1, FVC, FEV1/FVC) in children and adults with asthma: A systematic review
por: Abi-Ayad, Meryem, et al.
Publicado: (2023)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Retrospective Analysis of the Relationship between Decline in FEV(1) and Abdominal Circumference in Male Smokers: the Takahata Study
por: Sato, Masamichi, et al.
Publicado: (2012)

Predictors of accelerated FEV(1) decline in adults with airflow limitation—Findings from the Health2006 cohort
por: Baarnes, Camilla Boslev, et al.
Publicado: (2019)

67 CF patients with a declining FEV(1): At risk for acquisition of Burkholderia cepacia complex infection?
por: Willekens, J., et al.
Publicado: (2015)

Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD
por: Rosso, Aldana, et al.
Publicado: (2022)

Changes in Smoking Habits and Behaviors Following the Introduction and Spread of Heated Tobacco Products in Japan and Its Effect on FEV(1) Decline: A Longitudinal Cohort Study
por: Harada, Sei, et al.
Publicado: (2022)

Utility of FEV(1)/FEV(6) index in patients with multimorbidity hospitalized for decompensation of chronic diseases
por: Komal, Shakeel, et al.
Publicado: (2019)

Developing Grit, Motivation, and Resilience: To Give Up on Giving In
por: Whitfield, Karen M., et al.
Publicado: (2021)

Forced Expiratory Volume in 6 s (FEV(6)) and FEV(1)/FEV(6) Values as a Viable Alternative for Forced Vital Capacity (FVC) and FEV(1)/FVC Values During Pregnancy in South East Nigeria: A Preliminary Study
por: Nwagha, U, et al.
Publicado: (2014)

BMI is associated with FEV(1) decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials
por: Sun, Yilan, et al.
Publicado: (2019)

Accelerated FEV(1) decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients
por: Whittaker, Hannah R., et al.
Publicado: (2021)

Do Not Give Up
por: Roux, René Lynnette, et al.
Publicado: (2017)

FEV(1) inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure
por: Montaño, Martha, et al.
Publicado: (2014)

Genetic variation in TIMP1 but not MMPs predict excess FEV(1 )decline in two general population-based cohorts
por: van Diemen, CC, et al.
Publicado: (2011)

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation
por: Jenkins, Bradlee A., et al.
Publicado: (2014)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5f9dqmspmi0sa6mnfo2t2h52ua